How should I manage a 34-year-old Indian woman with intermittent chest pain when lying down, right calf cramps, a tibia/fibula intramedullary rod placed 7 years ago, recent use of combined estrogen‑containing oral contraceptives for one month, and low ferritin?

Immediate Discontinuation of Combined Oral Contraceptives Required

This patient must stop her estrogen-containing combined oral contraceptive immediately due to high risk of venous thromboembolism (VTE). The combination of recent combined hormonal contraceptive (CHC) use, leg symptoms in a limb with orthopedic hardware, and chest pain when lying down creates a concerning clinical picture that warrants urgent evaluation for VTE and immediate contraceptive change.

Critical Risk Assessment

VTE Risk Factors Present

This patient has multiple compounding risk factors for venous thromboembolism:

• Combined estrogen-containing contraceptive use: CHCs increase VTE risk 4-fold overall, with highest risk during the first year of use 1. Since she has only been using it for one month, she is in the highest-risk period 1.

• Orthopedic hardware with immobilization history: The tibial-fibular rod placement represents both prior trauma (a strong VTE provoking factor) and potential ongoing risk from hardware 1. Surgery and lower-limb fractures are strong provoking factors for VTE 2.

• Current leg cramping: Right calf cramping in the leg with hardware raises concern for deep vein thrombosis, particularly given concurrent chest pain.

• Chest pain when lying down: This positional chest pain could represent pulmonary embolism, pleuritic pain, or cardiac involvement.

Immediate Actions Required

1. Stop combined oral contraceptive today - formal contraindication exists with suspected VTE 1

2. Urgent clinical evaluation for VTE:

   • D-dimer testing
   • Lower extremity venous duplex ultrasound of the right leg
   • Consider CT pulmonary angiography or V/Q scan if chest pain persists
   • ECG and cardiac biomarkers to exclude cardiac causes

3. Assess for additional thrombotic risk factors:

   • Family history of VTE in first-degree relatives before age 60
   • Personal history of prior thrombotic events
   • Smoking status
   • BMI and obesity assessment

Alternative Contraception Strategy

Switch to progestin-only contraception once VTE is excluded or treated 1:

First-Line Options (No VTE Risk Increase)

• Levonorgestrel IUD (Mirena): No significant VTE risk, highly effective, lasts 5 years 1
• Desogestrel 75 mcg microdose progestin pill: No excess VTE risk demonstrated 1
• Etonogestrel implant: No significant VTE risk, highly effective for 3 years 1

If VTE is Confirmed

If this patient has acute VTE, combined estrogen-progestin contraception becomes formally contraindicated permanently 1. Management pathway:

• Acute phase: Discontinue all hormonal contraception, use barrier methods with emergency contraception access 1
• After acute treatment: Progestin-only methods (microdose or macrodose) may be prescribed 1
• Long-term: Levonorgestrel IUD or progestin-only pills are safest options 1

Management of Low Ferritin

The low ferritin requires separate attention but is not a contraindication to progestin-only contraception:

Iron Supplementation Strategy

• Oral iron supplementation: Ferrous sulfate 325 mg daily or ferrous fumarate 200 mg daily
• Dietary counseling: Increase iron-rich foods, vitamin C to enhance absorption
• Monitor response: Recheck ferritin and hemoglobin in 3 months

Contraceptive Benefits for Iron Status

Switching to progestin-only methods may actually improve iron status:

• Levonorgestrel IUD significantly reduces menstrual blood loss, improving iron stores over time 3
• Progestin-only pills often reduce menstrual bleeding
• Combined oral contraceptives reduce menstrual blood loss by ~40% 3, but this benefit is outweighed by VTE risk in this patient

Note: While iron-containing oral contraceptives exist (typically 25 mg elemental iron as ferrous fumarate for 7 days per cycle) 4, these are combined formulations and remain contraindicated in this patient due to VTE risk.

Critical Pitfalls to Avoid

1. Do not continue CHCs while "investigating" symptoms - the VTE risk is too high with her symptom complex

2. Do not assume leg cramping is "just muscle pain" - always evaluate for DVT in patients on CHCs with leg symptoms, especially with orthopedic hardware

3. Do not use transdermal patches or vaginal rings as alternatives - these non-oral CHC routes carry similar 3-4 fold increased VTE risk 1

4. Do not delay contraceptive counseling - provide barrier methods immediately upon CHC discontinuation to prevent unintended pregnancy

5. Do not forget thrombophilia screening if family history emerges - test for Factor V Leiden, prothrombin G20210A, protein C, protein S, and antithrombin if first-degree relative had VTE before age 60 1

Clinical Algorithm Summary

Step 1: Discontinue combined oral contraceptive immediately

Step 2: Urgent VTE workup (D-dimer, leg ultrasound, consider chest imaging)

Step 3: Provide barrier contraception temporarily

Step 4: If VTE excluded → transition to levonorgestrel IUD or progestin-only pill

Step 5: If VTE confirmed → treat anticoagulation per protocol, then consider progestin-only methods after multidisciplinary discussion

Step 6: Initiate iron supplementation for low ferritin

Step 7: Follow-up in 1-2 weeks to confirm VTE workup completion and contraceptive transition